Par, Paddock file reply brief supporting dismissal of FTC AndroGel suit
MLex Summary: Par Pharmaceuticals and Paddock Holdings have filed a reply brief supporting their motion to dismiss the US Federal Trade Commission's complaint alleging a pay-for-delay agreement involving the drug AndroGel....To view the full article, register now.
Already a subscriber? Click here to view full article